The Last Smile
On a Friday afternoon in December 2023, the employees of SmileDirectClub received an email informing them that the company — which had once been valued at $8.9 billion, which had shipped more than two million clear aligners to customers in the United States, Canada, the United Kingdom, Australia, and a half-dozen other countries, which had at its peak employed more than 6,000 people and operated nearly 300 retail locations called SmileShops in Walmarts and CVS stores and strip malls across the American suburban landscape — was ceasing all operations, effective immediately. There would be no severance for most. Customer treatment plans, some mid-course, would be abandoned. The aligners already in the mail would be the last ones. A federal bankruptcy judge in Houston would oversee the liquidation. The stock, which had debuted on the Nasdaq at $23 per share in September 2019, had already been delisted months earlier, trading in its final sessions at fractions of a penny. The enterprise that had promised to democratize orthodontics — to do for teeth what Warby Parker had done for eyeglasses, what Casper had done for mattresses, what every direct-to-consumer brand of the 2010s had promised to do for its respective category — ended not with a pivot or an acquisition or even a dignified wind-down, but with a bankruptcy filing, $900 million in debt, and a warehouse in Antioch, Tennessee full of 3D printers with nowhere to send their output.
The story of SmileDirectClub is not, in the conventional telling, a complicated one. Scrappy disruptor takes on entrenched industry. Incumbents fight back. Disruptor scales too fast, burns too much cash, runs into regulatory walls and clinical controversies, and dies. But that telling obscures something more interesting and more instructive. SmileDirectClub built, from scratch, a vertically integrated manufacturing and clinical infrastructure that was genuinely novel — a telehealth-enabled orthodontic system that eliminated the orthodontist's office entirely, replacing it with a mail-order model supported by remote dental professionals and proprietary 3D printing at industrial scale. The company's failure was not a failure of ambition or even, in certain respects, of execution. It was a failure of category selection, regulatory positioning, and the particular hubris that comes from believing that because incumbents are expensive and inconvenient, they must also be wrong.
By the Numbers
SmileDirectClub at Its Peak
$8.9BPeak market capitalization (September 2019)
$886MRevenue in FY2021 — the high-water mark
1.8M+Aligners shipped through 2022
~300SmileShop retail locations at peak
$1,950Average treatment price (vs. ~$5,000+ for Invisalign)
$900M+Total debt at bankruptcy filing
6,000+Employees at peak (reduced to ~1,800 by end)
$0.001Approximate final share price before delisting
The arc from $8.9 billion to zero took four years. Understanding why requires understanding not just the company's operating model and competitive dynamics, but the deeper architecture of the DTC boom itself — the venture-subsidized consumer surplus, the regulatory arbitrage dressed up as innovation, the assumption that any industry with high margins and low NPS scores was ripe for disruption. SmileDirectClub tested that thesis more aggressively than almost any company of its era. The market's verdict was unambiguous.
Nashville's Teeth
The founding mythology of SmileDirectClub begins where many DTC origin stories do: with a personal grievance transmuted into a business plan. Alex Fenkell and Jordan Katzman, childhood friends in suburban Detroit, were in their mid-twenties in 2014 when they began exploring the idea that clear aligner therapy — the technology Align Technology had commercialized with Invisalign starting in 1997 — could be delivered without the traditional orthodontic office visit. Fenkell, the son of a successful entrepreneur, had worn braces as a teenager and retained the memory of the expense and inconvenience. Katzman came from a family with deeper pockets and sharper business instincts; his stepfather was David Katzman, a Nashville-based serial entrepreneur who had built and sold Healtheon (later WebMD Health) and various other ventures, and who would become SmileDirectClub's chairman, largest individual shareholder, and, in many ways, the strategic brain behind the operation.
The insight was straightforward and, at the time, genuinely compelling. Invisalign charged orthodontists roughly $1,000–$1,500 per case for the aligners themselves. The orthodontist then charged the patient $4,000–$8,000 for the full treatment, with the markup covering the office visits, the impressions, the adjustments, the overhead of maintaining a clinical practice. What if you could cut the orthodontist out entirely — or at least replace the in-person visits with remote monitoring? You could 3D-print your own aligners, ship them directly to the consumer, and charge $1,895 for what competitors charged four times as much. The margin structure, on paper, was beautiful. The consumer value proposition was even better.
SmileDirectClub incorporated in 2014, shipped its first aligners in 2015, and by 2016 had attracted enough traction to draw the attention of strategic investors. The most consequential was Align Technology itself, which invested $46.7 million for a 19% stake in January 2016 — a decision that Align's leadership would come to regret with extraordinary intensity.
We're not trying to replace orthodontists. We're trying to reach the 85% of people who need treatment but can't afford it or won't go through the hassle.
The company's early operations were built around a surprisingly physical infrastructure. Customers could either order an impression kit by mail — a $49 box containing putty that the customer would bite into, then mail back — or visit a SmileShop, a retail storefront where a dental technician would perform a 3D scan of the customer's teeth using an iTero or similar intraoral scanner. The scan or impression was then reviewed by a licensed dentist or orthodontist (employed by or contracted with SmileDirectClub's affiliated dental practice, or by partner practices in certain states) who would create a treatment plan. If approved, the full set of aligners — typically 15–30 trays designed to be worn sequentially over four to six months — would be manufactured at SmileDirectClub's own facility and shipped to the customer's door.
This was the model's elegance and its vulnerability. The elegance was cost structure: by manufacturing in-house and eliminating the office visit, SmileDirectClub could offer treatment at roughly 60% less than the going rate. The vulnerability was clinical: orthodontic treatment is not a consumer product. Teeth are embedded in bone. Moving them incorrectly can cause root resorption, bite misalignment, gum recession, and in severe cases, tooth loss. The question of whether a remote dental professional reviewing a scan could safely supervise this process — without ever placing hands in the patient's mouth — would become the central controversy of SmileDirectClub's existence.
The Align Divorce
The relationship between SmileDirectClub and Align Technology deserves its own case study in strategic miscalculation. When Align invested in 2016, the logic was defensive: SmileDirectClub was building a channel that could expand the total addressable market for clear aligners by reaching mild-to-moderate cases that would never walk into an orthodontist's office. Align would supply the aligners (or at least the intellectual property and know-how), SmileDirectClub would supply the distribution, and both would benefit from the expansion.
The partnership unraveled within eighteen months. By mid-2017, SmileDirectClub had begun manufacturing its own aligners using HP's Multi Jet Fusion 3D printers — a direct competitive threat to Align's core manufacturing business. SmileDirectClub was also growing faster than Align had anticipated, and its price point was beginning to exert gravitational pull on the broader aligner market. In October 2017, Align sold its stake for approximately $54 million — a modest profit on the initial investment, but a catastrophic strategic error if SmileDirectClub succeeded. The two companies promptly sued each other. Align alleged patent infringement and trade secret misappropriation. SmileDirectClub countersued, alleging that Align was conspiring with the American Dental Association and state dental boards to restrict SmileDirectClub's ability to operate — an antitrust claim that would become a recurring theme.
The litigation was settled in 2020, with both parties agreeing to drop their claims. But the divorce reshaped both companies' strategies. Align launched its own direct-to-consumer channel (Invisalign Go, and later investments in lower-cost aligner brands), while SmileDirectClub doubled down on vertical integration, bringing virtually every step of the manufacturing process in-house.
⚖️
The Align Technology Entanglement
Strategic investment to bitter divorce
2016Align Technology invests $46.7M for 19% stake in SmileDirectClub, supplying aligner technology and clinical know-how.
2017SmileDirectClub begins in-house aligner manufacturing using HP 3D printers. Align sells its stake for ~$54M. Mutual lawsuits filed.
2019Both companies go to war in state legislatures and dental boards. Align's market cap exceeds $25B.
2020Litigation settled. Both parties drop claims. SmileDirectClub's market cap has fallen below $3B.
The Align breakup revealed something fundamental about SmileDirectClub's strategic position. Align had a 20-year head start in aligner technology, hundreds of patents, and deep relationships with the orthodontic community. SmileDirectClub's competitive advantage was not technological superiority — it was distribution arbitrage. The company's moat, such as it was, rested on its willingness to operate in a gray zone between retail and healthcare that Align, constrained by its relationships with dental professionals, could not easily enter. When Align proved willing to fight back — and when the dental profession rallied to Align's defense — that gray zone began to narrow.
The Factory in Tennessee
If SmileDirectClub's consumer-facing brand was pure DTC playbook — Instagram ads, celebrity endorsements, refer-a-friend programs — the operational backbone was something far more unusual. The company built what was, at the time, one of the largest clear aligner manufacturing facilities in the world: a 700,000-square-foot plant in Antioch, Tennessee, a Nashville suburb better known for auto parts distribution than dental technology.
Inside the Antioch facility, SmileDirectClub operated an end-to-end manufacturing system that started with digital treatment plans and ended with individually packaged aligner sets ready for shipment. The heart of the operation was a fleet of HP Multi Jet Fusion 3D printers — at peak, reportedly more than 60 — that produced the dental molds on which the aligners were thermoformed. Each customer's treatment plan required a unique set of molds, and each mold was printed, thermoformed (a clear plastic sheet heated and vacuum-sealed over the mold), trimmed, inspected, labeled, and packaged in a process that combined additive manufacturing with old-fashioned assembly-line discipline.
The scale was impressive. SmileDirectClub claimed to be producing over 50,000 unique aligner molds per day at peak capacity. The company's 2019 S-1 filing noted that it had invested heavily in automation and had driven its aligner manufacturing cost to approximately $200–$300 per full treatment set — a fraction of what it cost Align Technology to produce an Invisalign case, though the comparison was imperfect given differences in case complexity.
But scale created its own problems. The facility's fixed costs were enormous, and utilization rates became the critical variable. When customer acquisition slowed — as it did, dramatically, after the IPO — SmileDirectClub was stuck with a factory designed to serve a demand curve that had flatlined. The operating leverage that was supposed to amplify profitability instead amplified losses.
$8.9 Billion for Thirty Seconds
SmileDirectClub's IPO on September 12, 2019, was the kind of public offering that makes venture capitalists write Medium posts about the democratization of finance and makes short sellers begin sharpening their pencils. The company priced at $23 per share, giving it a fully diluted market capitalization of approximately $8.9 billion. On its first day of trading, the stock fell 28%, closing at $16.67. It was the worst first-day performance for a U.S. IPO of that size in nearly two decades.
The S-1 filing told a story of extraordinary growth and equally extraordinary losses. Revenue had grown from $146 million in 2017 to $423 million in 2018. But the company had never been profitable. Net losses were $75 million in 2017, $75 million in 2018, and were running at $100 million through the first half of 2019. Customer acquisition costs were rising. The average revenue per aligner case was declining slightly as the company pushed financing options (SmilePay, an installment plan at $85/month) that deferred revenue recognition and introduced credit risk.
We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.
The S-1 also revealed the company's unusual corporate structure. SmileDirectClub, Inc. — the publicly traded entity — was a holding company that owned a controlling interest in SDC Financial LLC, which in turn operated the business. The structure was a variation on the "Up-C" model popular with private-equity-backed IPOs, designed to provide tax benefits to pre-IPO investors (principally the Katzman family and venture investors including Kleiner Perkins and Clayton, Dubilier & Rice) through a tax receivable agreement. This TRA, which obligated the public company to pay pre-IPO holders 85% of certain tax savings, would become a source of investor frustration as the company's losses mounted — it was a mechanism designed for a profitable future that never arrived.
The investor who looked past the losses and saw the opportunity was betting on three things: that the clear aligner market was massive and underpenetrated; that SmileDirectClub's direct-to-consumer model would continue to acquire customers at reasonable cost; and that manufacturing scale would eventually flip the unit economics from loss-making to profitable. All three bets failed.
The Orthodontists' War
The most visceral opposition to SmileDirectClub came not from Align Technology — which, as a fellow corporate entity, waged its war through litigation and lobbying — but from the orthodontic profession itself. The American Association of Orthodontists (AAO) and the American Dental Association (ADA) treated SmileDirectClub as an existential threat to patient safety and professional autonomy, and they fought back with every tool available: state dental board complaints, legislative lobbying, social media campaigns, and an unrelenting drumbeat of clinical horror stories.
The clinical concerns were not invented. Orthodontic treatment, even for mild cases, involves biomechanical forces applied to living tissue. The risks of unsupervised or poorly supervised treatment include root resorption (shortening of the tooth root), malocclusion (bite problems that can cause TMJ disorders), and in rare cases, tooth devitalization. SmileDirectClub's model — in which a licensed dentist or orthodontist reviewed the initial scan and treatment plan but never physically examined the patient, and in which subsequent monitoring was conducted through the patient submitting photos via a smartphone app every 90 days — was, in the eyes of many practitioners, clinically reckless.
The counterargument, which SmileDirectClub made loudly and often, was that the company treated only mild-to-moderate cases, that its licensed dental professionals were qualified to make clinical judgments from scans, and that the real motivation behind the profession's opposition was economic protectionism. A $1,950 aligner from SmileDirectClub was a $5,000 Invisalign case that an orthodontist didn't get to bill.
Both arguments contained truth, and neither was sufficient. SmileDirectClub's clinical oversight model was genuinely thinner than traditional orthodontic care. And the orthodontic profession's opposition was genuinely motivated, at least in part, by economic self-interest. The tragedy for SmileDirectClub was that in a healthcare context, the regulatory system is designed to resolve such disputes in favor of the incumbents. State dental boards — staffed by practicing dentists and orthodontists — had the power to restrict or prohibit SmileDirectClub's operating model, and many did.
Between 2017 and 2022, SmileDirectClub faced regulatory challenges in more than a dozen states. Some states required that a dentist conduct an in-person examination before prescribing orthodontic treatment, effectively prohibiting SmileDirectClub's teledentistry model. Others imposed advertising restrictions or required that SmileDirectClub operate its SmileShops under the direct supervision of a licensed dentist (rather than using dental technicians supervised remotely). SmileDirectClub fought back with its own lobbying apparatus — spending over $5 million on lobbying between 2019 and 2022 — and filed antitrust complaints with the Federal Trade Commission, alleging that state dental boards were engaging in anticompetitive behavior.
In 2020, the FTC sent letters to multiple state dental boards warning them against imposing restrictions that could limit competition in the teledentistry market. It was a moral victory for SmileDirectClub, but a pyrrhic one. The regulatory patchwork remained, making state-by-state expansion costly and unpredictable, and the clinical controversies — amplified by social media, where dissatisfied customers posted photos of ill-fitting aligners and worsening bites — continued to erode the brand.
The AAO cautions consumers about the potential health risks of companies that sell orthodontic treatment with clear aligners directly to consumers without the direct, ongoing supervision of an orthodontist.
The Pandemic Paradox
COVID-19 should have been SmileDirectClub's moment. The pandemic shut down orthodontic offices nationwide, made in-person healthcare visits risky, and accelerated consumer adoption of telehealth across every medical category. A company whose entire model was built around remote dental care should have emerged from the lockdowns stronger than it entered.
Instead, SmileDirectClub stumbled. The SmileShops — which had become the company's primary customer acquisition channel, accounting for over 70% of new case starts — were forced to close during lockdowns. At-home impression kits, the alternative channel, had always had high abandonment rates (customers found the process messy and intimidating) and produced lower-quality scans than the in-store 3D scanners. Revenue fell from $750 million in FY2019 to $657 million in FY2020, a decline driven almost entirely by the SmileShop closures.
The company pivoted aggressively toward its impression-kit channel and launched a new product — a smartphone-based scanning system using the phone's camera — that was supposed to replace both the SmileShops and the impression kits. The technology never worked well enough to drive meaningful volume. SmileDirectClub also began exploring partnerships with dental practices, effectively reversing years of positioning itself as the anti-dentist alternative.
Revenue rebounded to $886 million in FY2021, the company's all-time high, but the growth was fueled by a combination of pent-up demand, aggressive marketing spend ($400+ million in sales and marketing in 2021), and financing incentives that extended payment terms and increased credit risk. Gross margins, which had been in the low 70s on a percentage basis in the pre-IPO period, compressed to the mid-to-high 60s as manufacturing costs rose and product mix shifted.
The underlying problem was customer acquisition cost. SmileDirectClub had always been a heavy advertiser — the company's marketing spend consistently ran at 40–50% of revenue — but the return on that spend was deteriorating. The easiest customers, the ones who were already interested in clear aligners and simply looking for a cheaper option, had already been reached. Each incremental customer was harder and more expensive to acquire, and the company was simultaneously fighting headwinds from negative press coverage, clinical controversies, and the reopening of orthodontic offices.
The CareCred Misadventure
In 2021, as the core aligner business plateaued, SmileDirectClub's management — now led by CEO David Katzman, who had replaced the co-founders in the top role — made an increasingly desperate series of strategic bets. The most notable was the launch of SmileDirectClub's own financing platform, branded as CareCred, which the company positioned as a vertical fintech play that could extend beyond dental care into other healthcare categories.
The logic was superficially compelling. SmileDirectClub's SmilePay financing program already provided installment plans to a majority of its customers. Why not build a standalone lending platform that could serve other healthcare providers? The answer, which became painfully obvious, was that SmileDirectClub had no competitive advantage in consumer lending, no expertise in credit underwriting at scale, and no balance sheet to absorb credit losses. The company's existing SmilePay portfolio was already experiencing rising delinquency rates — a 2022 SEC filing revealed that the company had written off approximately $82 million in customer receivables that year.
CareCred was quietly shelved in 2022. But it illustrated a pattern common to DTC companies in distress: the lunge toward platform adjacencies when the core business model is faltering. SmileDirectClub also invested in oral care products (whitening kits, electric toothbrushes, retainers) and international expansion, opening SmileShops in the UK, Australia, Canada, Germany, and several other markets. None of these initiatives generated meaningful revenue or reached profitability.
The Numbers That Told the Truth
The financial trajectory of SmileDirectClub is a study in the difference between revenue growth and value creation. The company generated cumulative revenues of approximately $3 billion between 2017 and 2022. In the same period, it generated cumulative net losses of approximately $1.6 billion and consumed roughly $1.3 billion in cash from operations. The cash burn was financed by a combination of IPO proceeds (approximately $1.1 billion raised in the 2019 offering), subsequent debt issuances (including $750 million in convertible notes in 2021), and asset-backed securitizations of its SmilePay receivables.
📉
SmileDirectClub Financial Trajectory
Revenue, losses, and the path to insolvency
| Year | Revenue | Net Loss | Marketing Spend | Employees |
|---|
| 2017 | $146M | ($75M) | ~$75M | ~2,000 |
| 2018 | $423M | ($75M) | ~$175M | ~4,000 |
| 2019 | $750M | ($387M) | ~$340M | ~5,500 |
| 2020 |
The 2022 revenue collapse — from $886 million to $474 million, a 46% decline — was the mortal wound. Customer acquisition costs had risen to unsustainable levels, repeat purchase rates were negligible (orthodontic treatment is a one-time purchase for most customers), and the negative press cycle had reached a tipping point. The company cut marketing spend, which reduced losses but also cratered revenue, creating a doom loop. By mid-2023, SmileDirectClub was burning through its remaining cash at approximately $30 million per month with no realistic path to profitability.
The Governance Question
To understand SmileDirectClub's final chapter, you must understand its corporate governance — or, more precisely, the absence of meaningful governance constraints on the Katzman family's control.
David Katzman, through his family's holdings and the dual-class share structure established at the IPO, controlled approximately 59% of the company's voting power throughout its public life. The dual-class structure gave Class B shares (held by pre-IPO investors) ten votes per share, compared to one vote per share for Class A shares (sold to the public). This is common enough in Silicon Valley founder-led companies, but SmileDirectClub was not a Silicon Valley company led by a visionary founder-engineer. It was a Nashville-based consumer healthcare company led by the stepfather of one of the co-founders, a man whose previous ventures had been in digital media and healthcare services, not in clinical dentistry or consumer products.
Katzman's control meant that the board — which included his wife, Susan Katzman, as well as several individuals with close personal or business ties to the family — was effectively an advisory body rather than a governing one. Related-party transactions were significant: the company leased its Antioch manufacturing facility from a Katzman-affiliated entity, and the tax receivable agreement funneled hundreds of millions in potential future tax benefits to pre-IPO holders.
The governance structure also meant that the company's strategic pivots — the push into international markets, the CareCred venture, the decision to maintain high marketing spend even as returns deteriorated — were not subject to the kind of independent board scrutiny that might have imposed discipline. When SmileDirectClub needed to cut costs radically in 2022 and 2023, the cuts came too late and too slowly, hampered by a leadership team that had built the company's identity around growth and was psychologically incapable of managing decline.
Our dual class structure has the effect of concentrating voting control with holders of our Class B common stock, which will limit or preclude your ability to influence corporate matters.
The Liquidation
SmileDirectClub filed for Chapter 11 bankruptcy protection in the Southern District of Texas on September 29, 2023. The filing listed assets of $558 million and liabilities of $1.06 billion. The company initially proposed a reorganization plan that would have converted its debt to equity and allowed it to continue operating in a slimmed-down form, focusing on a smaller set of U.S. markets.
The reorganization never happened. In December 2023, the company converted its filing to Chapter 7 — a full liquidation. The reasons were multiple: the company could not stop the cash bleed fast enough to make the reorganization economics work; potential acquirers (including several private equity firms that conducted due diligence) walked away after assessing the regulatory and reputational liabilities; and the customer pipeline, which had been the company's only remaining asset of real value, had dried up entirely as news of the bankruptcy spread.
The liquidation left behind a trail of creditors, abandoned customers, and unanswered questions. An estimated 100,000 customers were mid-treatment when the company ceased operations, with no mechanism to continue or transfer their care. Class-action lawsuits had already been filed on behalf of customers alleging clinical harm. The FDA had received over 1,400 adverse event reports related to SmileDirectClub aligners between 2016 and 2023, including reports of tooth damage, nerve damage, and bite misalignment. Whether these rates were meaningfully different from those of orthodontic treatment generally was a matter of fierce debate — one that the company's closure ensured would never be definitively resolved.
The 3D printers in Antioch were sold at auction. The SmileShop leases were terminated. The HP Multi Jet Fusion machines — the physical manifestation of SmileDirectClub's manufacturing ambition — were purchased by a liquidation firm for pennies on the dollar. The brand itself, the SmileDirectClub name and intellectual property, was acquired in bankruptcy by a group that has made no public announcement of plans to revive it.
What the Wreckage Reveals
SmileDirectClub's failure contains lessons that extend far beyond dentistry. The company was, in many ways, the purest expression of the DTC thesis of the 2010s: that any industry with high incumbent margins, low consumer satisfaction, and a product that could be shipped in a box was ripe for disruption by a venture-backed startup with a strong brand, a digital-first customer acquisition engine, and a willingness to operate in regulatory gray zones until the rules caught up.
The thesis was not entirely wrong. SmileDirectClub did reach millions of consumers who had never seriously considered orthodontic treatment. It did force Align Technology to accelerate its own lower-cost offerings. It did demonstrate that teledentistry — the remote delivery of dental care — was technically feasible at scale. These were real contributions, and they survived the company's death.
But the thesis underestimated several forces that, in combination, proved lethal. The regulatory environment for healthcare is fundamentally different from the regulatory environment for mattresses or eyeglasses. The clinical risks of orthodontic treatment are real, not manufactured by incumbents. Customer acquisition costs in a one-time-purchase category with no recurring revenue are structurally brutal. And the DTC model, which works beautifully when you are selling a commodity product at a lower price with a better brand experience, breaks down when the product is a medical treatment whose quality depends on professional judgment that cannot be easily automated or scaled.
The core question is whether SmileDirectClub is a technology company that happens to sell aligners, or a dental company with a good website. The valuation assumes the former; the business model suggests the latter.
The ghost of SmileDirectClub haunts every subsequent attempt to apply the DTC playbook to healthcare. Hims & Hers, Ro, Cerebral, Done — each has navigated the tension between consumer convenience and clinical rigor differently, with varying degrees of success and controversy. SmileDirectClub was the most ambitious of the lot, and its ambition was precisely what destroyed it. The company didn't just want to sell a healthcare product online. It wanted to build the factory, train the technicians, design the software, underwrite the financing, and fight the regulators — all simultaneously, all with venture capital's impatience and public market investors' quarterly scrutiny.
In the Antioch facility, after the auctions were complete and the machines removed, what remained was the building itself — a vast, empty box in suburban Nashville, its loading docks sealed, its parking lot chain-linked, a monument to the distance between a compelling pitch deck and a sustainable business. The sign out front, white letters on blue, was the last thing to come down. SMILEDIRECTCLUB. The font was friendly. The teeth were always white.
SmileDirectClub's story is not merely a cautionary tale of a company that burned through $1.3 billion and left 100,000 customers mid-treatment. Buried within the wreckage are genuine operating insights — about vertical integration, regulatory strategy, category selection, and the limits of the direct-to-consumer model when applied to complex, regulated products. The principles below are drawn from what SmileDirectClub got right, what it got catastrophically wrong, and what operators in adjacent categories can learn from both.
Table of Contents
- 1.Price is a weapon; cost structure is the war.
- 2.Vertical integration without vertical expertise is a trap.
- 3.Regulatory moats cut both ways.
- 4.One-time purchases demand earned media, not paid growth.
- 5.Don't confuse your customer's complaint with your product's solution.
- 6.Strategic investors are strategic for their benefit, not yours.
- 7.Healthcare DTC requires clinical credibility as a core competency.
- 8.The factory is a bet on the demand curve — get it wrong and it eats you.
- 9.Governance is operating leverage.
- 10.Know when the thesis has been disproven.
Principle 1
Price is a weapon; cost structure is the war.
SmileDirectClub's $1,950 price point was its most potent competitive asset. At roughly 60% less than Invisalign, it expanded the addressable market dramatically — the company estimated that 85% of Americans with malocclusion were untreated, and price was the primary barrier. The SmilePay financing option ($85/month, no credit check, no down payment) reduced the friction further. In a category where the incumbent value proposition was "pay $5,000 and visit the orthodontist 15 times over 18 months," SmileDirectClub's offer was genuinely revolutionary.
But the price was not sustainable at the company's actual cost structure. Manufacturing costs were manageable (~$200–$300 per case), but customer acquisition costs consumed the margin. SmileDirectClub spent $340 million in marketing in 2019, $280 million in 2020, and $405 million in 2021 — consistently 40–50% of revenue. When you subtract manufacturing, shipping, clinical labor, SmileShop operations, and corporate overhead, the contribution margin per case was thin to negative for much of the company's life. The price was a weapon, but the cost structure behind it was a liability.
Benefit: Radical price disruption expands the addressable market and creates a consumer value proposition that incumbents cannot easily match without cannibalizing their own margins.
Tradeoff: If your cost structure doesn't support the price at scale — if customer acquisition costs and operational complexity eat the margin — you are subsidizing market expansion with investor capital, not building a business.
Tactic for operators: Before launching a price-disruptive product, model the unit economics at 3x your current scale, not at infinite scale. If the contribution margin per unit is negative or break-even at realistic volume, the price point is a customer acquisition subsidy, not a business model.
Principle 2
Vertical integration without vertical expertise is a trap.
SmileDirectClub's decision to build its own manufacturing facility, develop its own treatment planning software, and create its own clinical oversight infrastructure was, on paper, a masterclass in vertical integration. Control the entire value chain and you control the cost structure, the quality, and the customer experience. This is the Zara model, the Tesla model, the model that every MBA case study celebrates.
The flaw was that SmileDirectClub was vertically integrated across two fundamentally different domains — consumer technology and clinical dentistry — and its leadership had deep expertise in only one. The manufacturing operation was impressive. The marketing machine was sophisticated. The clinical oversight model was, by the profession's standards, dangerously thin. The company's affiliated dental practices were staffed by licensed professionals, but the ratio of dentists to patients, the reliance on photo-based remote monitoring, and the limited ability to intervene when treatments went off-track were structural weaknesses that no amount of 3D printing prowess could compensate for.
What SmileDirectClub controlled — and what it didn't
| Function | Owned/Controlled | Quality Assessment |
|---|
| Customer acquisition (digital + retail) | Yes | Strong |
| 3D scanning / impressions | Yes (SmileShops + kits) | Adequate |
| Aligner manufacturing (3D print + thermoform) | Yes (Antioch facility) | Strong |
| Treatment planning software | Yes |
Benefit: Vertical integration gives you control over cost, quality, and the customer experience — the holy trinity of DTC operations.
Tradeoff: When you integrate into a domain where you lack deep expertise (clinical care, financial underwriting, regulatory compliance), you inherit the risks of that domain without the institutional knowledge to manage them. The weakest link in your vertical stack determines your ceiling.
Tactic for operators: Before vertically integrating into a new function, ask: "Do we have world-class expertise in this domain, or are we assuming that operational competence in adjacent domains transfers?" If the answer is the latter, consider partnering rather than building.
Principle 3
Regulatory moats cut both ways.
SmileDirectClub's relationship with regulation was paradoxical. The company positioned itself as a disruptor fighting entrenched incumbents who used regulatory capture to protect their economic rents. This narrative was not entirely wrong — state dental boards, staffed by practicing dentists, did have structural incentives to restrict competition. But SmileDirectClub's leadership made a catastrophic strategic error: they treated regulation as an obstacle to be overcome through lobbying and litigation rather than as a signal about the nature of the market they were entering.
In healthcare, regulation exists in part because the information asymmetry between provider and patient is profound, and the consequences of error are irreversible. You cannot return a misaligned bite. SmileDirectClub spent over $5 million on lobbying and filed antitrust complaints with the FTC, winning some battles (the FTC's warning letters to dental boards) and losing others (state-level restrictions that limited or prohibited its model). But the energy and capital consumed by the regulatory fight was enormous — and it diverted resources from the clinical credibility-building that might have defanged the opposition.
Benefit: If you can change the regulatory framework in your favor, you can create a moat that protects your business model from competitors who play by the old rules.
Tradeoff: Fighting regulators in a healthcare context is extraordinarily expensive, unpredictable, and reputation-destroying. Every regulatory battle generates negative press coverage that directly undermines consumer trust — the asset you most need.
Tactic for operators: If your business model requires regulatory change to function, price that into your capital plan and timeline. Better still: design the model to be unambiguously compliant with existing regulation, then lobby for expansion from a position of clinical strength rather than adversarial defiance.
Principle 4
One-time purchases demand earned media, not paid growth.
The deepest structural flaw in SmileDirectClub's unit economics was the absence of recurring revenue. Orthodontic treatment is a one-time purchase for most consumers. Once your teeth are straight, you do not buy another set of aligners. (Retainers, which SmileDirectClub sold, were a modest aftermarket product.) This meant that SmileDirectClub had to acquire a new customer for every dollar of revenue — there was no subscription base, no retention flywheel, no compounding cohort economics.
In a one-time-purchase category, customer acquisition cost is the business. And SmileDirectClub's CAC was brutal: at the company's scale, each new case start cost approximately $500–$800 in marketing and sales expense. With an average selling price of $1,950 and all-in costs (manufacturing, clinical, operational, corporate overhead) of $1,400–$1,600, the margin per case was razor-thin — and that's before accounting for the credit losses on SmilePay receivables.
The DTC brands that thrived in one-time-purchase categories — Warby Parker is the closest analog — did so by building such powerful brand affinity and word-of-mouth that organic and earned media drove a significant share of customer acquisition. SmileDirectClub's brand, by contrast, was perpetually under siege from clinical controversies and regulatory battles. The earned media was predominantly negative.
Benefit: Paid media is controllable and scalable in the short term — you can dial spend up or down with precision, making revenue growth predictable.
Tradeoff: In a one-time-purchase category with no recurring revenue, paid media dependency creates a treadmill. The moment you reduce spend, revenue collapses. The only escape is brand strength sufficient to drive organic demand — and that requires trust, which SmileDirectClub could never fully establish.
Tactic for operators: If your product is a one-time purchase, your marketing strategy must prioritize trust-building and referral mechanics over paid acquisition. Invest in clinical credibility, customer success stories, and community — the assets that compound — rather than Facebook ads, which decay.
Principle 5
Don't confuse your customer's complaint with your product's solution.
SmileDirectClub correctly identified the consumer pain point: orthodontic treatment was too expensive, too inconvenient, and too time-consuming. But the company's solution — eliminate the orthodontist entirely — was not the only possible response to that pain point, and it was arguably the most dangerous.
An alternative model might have partnered with orthodontists rather than antagonizing them, using technology to reduce the number of office visits and the cost of treatment while preserving the clinical oversight that patients needed and regulators required. This is, in fact, the model that Align Technology eventually moved toward with Invisalign Go — a system designed for general dentists to treat mild cases, with orthodontist consultation available for complex ones. It's also the model that companies like Candid (later acquired by Byte, which was acquired by Dentsply Sirona) pursued: a hybrid approach with in-person scans and orthodontist-supervised treatment plans.
SmileDirectClub's refusal to compromise on the fully remote model — a refusal driven by David Katzman's conviction that the dental profession was a cartel and by the company's cost structure, which required eliminating the orthodontist's fee to hit the $1,950 price point — was the strategic choice that invited the most intense opposition and the most damaging clinical controversies.
Benefit: A pure DTC model, if it works, creates maximum cost advantage and maximum competitive differentiation.
Tradeoff: When the customer's complaint is "this is too expensive and inconvenient" and your solution is "we'll remove the expert from the process entirely," you may be solving for cost at the expense of quality — and in healthcare, quality failures are existential.
Tactic for operators: Separate the customer's complaint into its component parts. If the complaint is about cost, convenience, and access, design solutions that address each independently. Eliminating the most expensive component (the professional) is the most dramatic solution and the most risky. Sometimes the right answer is to make the professional cheaper or more accessible, not to make them disappear.
Principle 6
Strategic investors are strategic for their benefit, not yours.
Align Technology's $46.7 million investment in SmileDirectClub in 2016 was framed at the time as a partnership — the market leader embracing innovation. In reality, it was a surveillance operation. Align gained access to SmileDirectClub's customer data, manufacturing processes, and growth trajectory. When SmileDirectClub began manufacturing its own aligners — threatening Align's core business — Align exited, weaponized the intelligence it had gathered, and launched competing products.
SmileDirectClub, for its part, gained $46.7 million in funding and Align's imprimatur of clinical legitimacy. But it traded something more valuable: strategic optionality. With Align as a shareholder, SmileDirectClub was constrained in its ability to partner with or acquire other aligner manufacturers. And when the relationship soured, SmileDirectClub had given its most dangerous competitor an intimate understanding of its operations.
Benefit: Strategic investors bring capital, credibility, and industry expertise that pure financial investors cannot.
Tradeoff: The strategic investor's interests are aligned with yours only so long as your success does not threaten their core business. The moment it does, they become your most informed competitor.
Tactic for operators: If you take strategic capital, negotiate ironclad information walls and non-compete provisions. Better still: ask whether the strategic investor's long-term interests are structurally aligned with yours, or only aligned at the current scale. If the alignment breaks at 10x your current size, the investment will break too.
Principle 7
Healthcare DTC requires clinical credibility as a core competency.
Every successful healthcare company — from Johnson & Johnson to UnitedHealth to the Mayo Clinic — has clinical credibility as a foundational asset. SmileDirectClub treated clinical credibility as a marketing problem rather than an operational one. The company published studies showing patient satisfaction rates above 90% and cited the credentials of its affiliated dental professionals. But it never invested in the kind of independent clinical research, peer-reviewed publications, and professional endorsements that would have established its model's safety and efficacy beyond reasonable doubt.
The absence of that credibility left the company vulnerable to every anecdote, every viral social media post of a botched case, every newspaper story about a patient whose bite was ruined. In healthcare, the burden of proof falls on the disruptor, not the incumbent. SmileDirectClub never internalized this.
Benefit: Clinical credibility, once established, is a durable moat — it builds trust with consumers, regulators, and the professional community simultaneously.
Tradeoff: Building clinical credibility is slow, expensive, and unglamorous. It requires multi-year longitudinal studies, independent peer review, and genuine engagement with the professional community that may be hostile to your model.
Tactic for operators: If you are building a healthcare product, invest in clinical evidence the way a pharmaceutical company invests in clinical trials — as the foundation of the entire enterprise, not as an afterthought. Budget 3–5% of revenue for independent clinical research from day one.
Principle 8
The factory is a bet on the demand curve — get it wrong and it eats you.
SmileDirectClub's 700,000-square-foot Antioch facility, with its fleet of 60+ HP 3D printers, was designed for a world in which the company was processing 50,000+ molds per day and growing. When demand plateaued in 2022 and collapsed thereafter, the facility became a monument to fixed costs. Lease payments, depreciation, maintenance, and staffing for a factory designed to serve a million customers a year don't scale down gracefully when you're serving 300,000.
This is the dark side of vertical integration in a demand-uncertain business. Outsourced manufacturing is more expensive per unit but more forgiving per scenario — you can adjust volume without carrying idle capacity. SmileDirectClub chose the opposite: maximum control, maximum fixed cost, maximum operating leverage in both directions.
Benefit: In-house manufacturing at scale drives unit costs to levels that outsourced competitors cannot match, creating a structural cost advantage.
Tradeoff: Fixed manufacturing capacity is a bet on the demand curve. If demand falls short, the fixed costs amplify losses instead of amplifying profits. The factory that was supposed to be a competitive weapon becomes an anchor.
Tactic for operators: Before committing to large-scale in-house manufacturing, stress-test the business plan against a demand shortfall of 30–50%. If the company cannot survive two years at 50% utilization, the manufacturing bet is too large relative to demand certainty.
Principle 9
Governance is operating leverage.
SmileDirectClub's dual-class share structure gave the Katzman family 59% of voting control with a fraction of the economic interest. This structure insulated management from shareholder pressure, which can be valuable when a company needs to make long-term investments that short-term investors would resist. But in SmileDirectClub's case, it insulated management from accountability during a period when the company desperately needed to cut costs, pivot strategy, and potentially explore a sale — actions that entrenched management resisted or delayed.
The related-party transactions (facility leases, the tax receivable agreement), the board composition (which included family members and close associates), and the absence of an independent strategic review committee all contributed to decisions being made in the interest of insiders rather than the business. When the company finally filed for bankruptcy, the governance structure that was supposed to protect long-term vision had instead protected long-term denial.
Benefit: Founder or family control can provide strategic continuity and insulation from short-term market pressures.
Tradeoff: Without independent governance mechanisms, control structures become mechanisms for entrenchment. In a company that needs radical change, concentrated control can prevent the very decisions that would save the business.
Tactic for operators: If you maintain voting control, voluntarily establish governance guardrails — an independent board majority, a related-party transaction committee, and a board-level review of strategic alternatives that triggers automatically if the company misses financial targets for two consecutive quarters.
Principle 10
Know when the thesis has been disproven.
The most painful lesson of SmileDirectClub is the simplest. By late 2021, the evidence was overwhelming that the company's core thesis — that a fully remote, DTC orthodontic model could achieve profitability at scale — had been disproven. Customer acquisition costs were rising. Regulatory headwinds were intensifying. Clinical controversies were accelerating. Revenue growth had peaked and reversed. Cash was hemorrhaging.
A different management team, with different incentives and different governance constraints, might have recognized this and acted — by pursuing a sale to a strategic acquirer (Align, Dentsply Sirona, or Henry Schein were all logical buyers at various points), by radically restructuring the model toward a hybrid approach, or by returning remaining capital to shareholders. Instead, SmileDirectClub doubled down — launching CareCred, expanding internationally, increasing marketing spend — burning through the last of its capital in pursuit of a growth trajectory that had already reversed.
The sunk cost fallacy, at corporate scale, is lethal.
Benefit: Strategic conviction is essential for any company trying to build something new. Without it, you pivot at every headwind and never achieve the scale necessary to validate the model.
Tradeoff: Conviction unchecked by evidence becomes delusion. The difference between a visionary founder and a delusional one is not temperament — it's the willingness to define, in advance, the conditions under which the thesis has been falsified.
Tactic for operators: At the start of any venture, define the kill criteria. "If we haven't achieved X by Y date, we will explore strategic alternatives." Write it down. Share it with the board. Make it a governance commitment, not a mental note. The founders who build the biggest companies are not the ones who never quit — they are the ones who know exactly when to quit and have the courage to do it.
Conclusion
The Distance Between a Pitch and a Business
SmileDirectClub's ten principles, taken together, describe a company that was better at identifying opportunities than at building the institutional capabilities required to capture them durably. The price disruption was real. The manufacturing innovation was real. The consumer pain point was real. What was missing was the clinical credibility, the governance discipline, the demand-side humility, and the strategic flexibility that separate a compelling pitch from a sustainable business.
The DTC playbook — compelling brand, digital-first acquisition, venture-subsidized pricing, vertical integration — works brilliantly for commodity products with high repurchase rates and low clinical risk. Toothbrushes, not teeth. When the same playbook is applied to a regulated healthcare product with significant clinical risk, no recurring revenue, and an organized professional opposition, the outcome is predictable. SmileDirectClub proved it, at a cost of $1.6 billion in losses and millions of half-treated smiles.
The operators who learn from SmileDirectClub will not learn to avoid ambition. They will learn to match ambition with institutional depth — to build the clinical evidence, the regulatory relationships, the governance structures, and the unit economics that turn a disruptive insight into a durable enterprise. The ones who don't will find their own version of the Antioch factory: a beautiful machine, perfectly engineered, with nothing left to print.
Part IIIBusiness Breakdown
The Business at a Glance
Terminal Snapshot
SmileDirectClub at Liquidation (September 2023)
$0Market capitalization (delisted)
~$100MEstimated 2023 partial-year revenue
$900M+Total debt at bankruptcy filing
$558MListed assets in bankruptcy filing
$1.06BListed liabilities in bankruptcy filing
~1,800Employees at time of closure
0SmileShops operating post-liquidation
~100KCustomers mid-treatment at closure
SmileDirectClub was, at the time of its bankruptcy, a company in terminal decline. Revenue had fallen from a peak of $886 million in FY2021 to $474 million in FY2022 and was on pace for roughly $100 million annualized in 2023 before operations ceased. The company had never generated a full-year operating profit. Cumulative net losses from inception through closure exceeded $1.6 billion. The balance sheet was deeply insolvent, with liabilities exceeding assets by more than $500 million.
What makes the financial autopsy instructive is not the magnitude of the failure — plenty of companies have lost more — but the speed and thoroughness of the unraveling. SmileDirectClub went from a $8.9 billion IPO valuation to Chapter 7 liquidation in just over four years, a trajectory that illustrates how quickly a high-fixed-cost, high-CAC business can spiral when growth reverses.
How SmileDirectClub Made Money
SmileDirectClub's revenue model was deceptively simple: sell clear aligner treatment plans directly to consumers, either at full price or through a financing plan.
SmileDirectClub's revenue streams at peak (FY2021)
| Revenue Stream | FY2021 (est.) | % of Total | Mechanism |
|---|
| Aligner treatment (upfront payment) | ~$350M | ~40% | One-time payment of $1,950 |
| SmilePay (installment plan) | ~$440M | ~50% | $2,050 total ($85/mo, 24 months, 0% interest) |
| Ancillary products (retainers, whitening, etc.) | ~$50M | ~5% | Direct e-commerce sales |
| International | ~$46M | ~5% | Same model, localized pricing |
The SmilePay financing program was a double-edged sword. It dramatically lowered the barrier to entry — $85/month versus $1,950 upfront — and drove the majority of case starts. But it introduced credit risk (the company was effectively its own lender), deferred cash collection, and required the company to estimate and reserve for write-offs. In FY2022, SmileDirectClub wrote off approximately $82 million in uncollectible SmilePay receivables, representing roughly 15–18% of SmilePay originations. The credit quality of the customer base was, by any lending standard, subprime — these were consumers who, by definition, could not or would not pay $5,000 for orthodontic treatment.
Unit economics per case, at the company's scale:
- Average selling price: ~$1,950 (blended between upfront and SmilePay)
- Cost of goods sold (manufacturing + clinical labor): ~$500–$600
- Gross margin: ~$1,350–$1,450 (~70%)
- Customer acquisition cost (marketing + SmileShop operations): ~$700–$900
- Contribution margin pre-overhead: ~$450–$750
- Corporate overhead allocation per case: ~$400–$600
- Net contribution per case: Approximately breakeven to slightly negative
The gross margin looked healthy. The contribution margin after marketing looked survivable. But there was no operating leverage — corporate overhead (technology, G&A, interest on debt) consumed whatever was left. SmileDirectClub needed dramatically higher volume to spread its fixed costs, and volume was moving in the wrong direction.
Competitive Position and Moat
SmileDirectClub operated in the clear aligner market, a segment of the broader orthodontic industry estimated at $8–$12 billion globally. Its competitive position was defined by price leadership and direct-to-consumer distribution — but its moat was shallow by any structural measure.
SmileDirectClub vs. key competitors at time of bankruptcy
| Company | Revenue (FY2022) | Model | Price Point | Status |
|---|
| Align Technology (Invisalign) | $3.7B | Professional-channel (orthodontists/dentists) | $3,000–$8,000 | Dominant |
| SmileDirectClub | $474M | DTC (remote + SmileShops) | $1,950 | Bankrupt |
| Byte (Dentsply Sirona) |
Moat assessment:
- Brand recognition: Moderate. SmileDirectClub achieved high unaided awareness (estimated at 40%+ among target demographics), but brand sentiment was mixed due to clinical controversies. Net Promoter Scores were inconsistent — the company claimed 90%+ satisfaction, but third-party surveys and review aggregators told a more complicated story.
- Cost advantage (manufacturing): Real but insufficient. The Antioch facility gave SmileDirectClub a genuine manufacturing cost advantage over competitors who outsourced production. But cost advantage in manufacturing was not the binding constraint — customer acquisition cost was.
- Network effects: None. Orthodontic treatment is a one-time purchase with no social or network component. One customer's use of SmileDirectClub does not make the product more valuable for the next customer.
- Switching costs: None. Pre-treatment, customers could choose any provider. Mid-treatment, customers were locked in — but this created customer captivity rather than loyalty, and it became a liability when the company shut down.
- Regulatory advantage: Negative. SmileDirectClub's operating model was under active regulatory challenge in multiple jurisdictions. Rather than creating barriers to entry, the regulatory environment created barriers to SmileDirectClub's own operations.
- IP / Patents: Minimal. The company held patents related to its manufacturing process and treatment planning software, but these were not broad enough to prevent competitors from building similar systems.
The honest assessment: SmileDirectClub's competitive position rested on its willingness to operate a model that more cautious companies would not attempt, at a price point that more disciplined companies would not offer. When the willingness proved unsustainable and the price point proved unprofitable, the competitive position evaporated.
The Flywheel That Didn't Fly
SmileDirectClub's intended flywheel followed a classic DTC loop:
The reinforcing cycle SmileDirectClub envisioned — and where it broke
Step 1Low price ($1,950) attracts high volume of customers who are priced out of traditional orthodontics.
Step 2High volume drives manufacturing utilization at Antioch, reducing per-unit cost and improving gross margins.
Step 3Satisfied customers generate word-of-mouth referrals, reducing customer acquisition cost over time.
Step 4Lower CAC and higher margins fund further marketing investment, expanding the customer base and brand awareness.
Step 5Scale and brand strength create barriers to entry for competitors, allowing SmileDirectClub to maintain pricing power.
The flywheel broke at Step 3. Satisfied customers did not generate sufficient word-of-mouth to meaningfully reduce CAC, because: (a) orthodontic treatment is a private, infrequent purchase that people rarely discuss publicly; (b) clinical controversies generated counter-word-of-mouth that neutralized positive referrals; and (c) the company's aggressive social media advertising, which was the primary acquisition channel, had diminishing returns as the easiest-to-reach customers were acquired first.
Without the CAC reduction at Step 3, the flywheel became a treadmill: more marketing spend produced more customers, but at rising cost per customer, requiring more marketing spend to maintain revenue, in a cycle that consumed cash rather than generating it. The factory at Antioch amplified this dynamic — its fixed costs demanded high utilization, which demanded high customer volume, which demanded high marketing spend.
Growth Drivers and Strategic Outlook
At the time of its bankruptcy, SmileDirectClub had identified several growth vectors, none of which had achieved sufficient traction to alter the company's trajectory:
-
International expansion. The company operated in nine countries outside the U.S. as of early 2023, with the UK and Australia as the largest international markets. Combined international revenue was estimated at less than $50 million annually — too small to move the needle and burdened by the same regulatory and clinical challenges as the U.S. market, plus the additional complexity of operating across jurisdictions.
-
SmileShop partner model. SmileDirectClub had begun partnering with Walmart and CVS to place SmileShops inside existing retail locations, reducing the fixed cost of standalone storefronts. The model showed some promise — Walmart locations had lower operating costs and higher foot traffic — but the partnership was still nascent when the company filed for bankruptcy.
-
Oral care products. Whitening kits, electric toothbrushes, and retainers were positioned as a product extension that could generate recurring revenue from existing customers. Revenue from these products never exceeded 5% of total sales.
-
CareCred / financing platform. As discussed, this venture into consumer healthcare lending was shelved in 2022 after failing to gain traction.
-
Telehealth platform licensing. SmileDirectClub explored licensing its teledentistry platform to other healthcare providers, positioning the technology as a standalone product. This concept never progressed beyond early-stage discussions.
The TAM argument — that 85% of Americans with malocclusion were untreated, representing a multi-billion-dollar opportunity — was always theoretically valid. The question was whether SmileDirectClub's specific model could capture that TAM at a cost that permitted profitability. The evidence, by 2022, was conclusive: it could not.
Key Risks and Debates
The following risks were not hypothetical — they materialized and contributed directly to the company's failure:
1. Regulatory risk (materialized). State dental boards in Alabama, California, Georgia, and over a dozen other states imposed restrictions on SmileDirectClub's operating model, including requirements for in-person examinations, supervision mandates, and advertising limitations. Each restriction increased operating costs and reduced the addressable market. The regulatory environment was getting stricter, not more permissive, at the time of bankruptcy.
2. Clinical safety liability (materialized). Over 1,400 adverse event reports were filed with the FDA between 2016 and 2023. Class-action lawsuits were filed on behalf of patients alleging clinical harm. While SmileDirectClub disputed the significance of these reports (noting that adverse event rates must be assessed relative to the total patient population), the reputational damage was severe and ongoing.
3. Customer acquisition cost spiral (materialized). CAC rose from an estimated $400–$500 per case in 2017–2018 to $700–$900 by 2021–2022 as the company exhausted its most responsive customer segments and faced increasing competition from Byte, Candid, and Align's own lower-cost offerings.
4. Credit risk from SmilePay (materialized). Write-offs on SmilePay receivables reached $82 million in FY2022, representing a loss rate that would have been considered catastrophic in any consumer lending context. The company was extending credit to subprime borrowers without the underwriting infrastructure or balance sheet reserves of a financial institution.
5. Concentration of control / governance risk (materialized). The Katzman family's voting control prevented independent strategic oversight during the period when the company most needed it. The dual-class structure, which was designed to protect long-term vision, instead protected strategic inertia.
Why SmileDirectClub Matters
SmileDirectClub matters not because it was a great company — by conventional financial measures, it was a catastrophe — but because it was the most ambitious and most revealing test case for a thesis that shaped an entire generation of startups. The thesis: that direct-to-consumer distribution, venture-backed price disruption, and digital-first customer acquisition could transform any industry characterized by high incumbent margins and low consumer satisfaction.
The thesis was partially correct. SmileDirectClub proved that millions of consumers wanted cheaper, more convenient orthodontic care. It proved that clear aligners could be manufactured at industrial scale using 3D printing. It proved that teledentistry was technically feasible. These are not trivial contributions — Align Technology's own strategic evolution toward lower-cost, broader-access aligner products was accelerated by SmileDirectClub's competitive pressure.
But the thesis was fatally incomplete. It underestimated the structural advantages of incumbents in regulated healthcare. It overestimated the portability of the DTC playbook from consumer goods to clinical services. It ignored the fundamental asymmetry of healthcare innovation: the cost of a failure is not a returned product or a refunded subscription, but a damaged body and a legal liability. And it assumed that customer acquisition cost was a variable that would decline with scale, when in a one-time-purchase category with no network effects and active professional opposition, the opposite proved true.
The operators who study SmileDirectClub will find not a simple morality tale but a complex engineering failure — a machine with individually impressive components (the factory, the brand, the price point, the digital infrastructure) that could not be made to work as a system because the system depended on a clinical credibility it never built and a unit economics it never achieved. The lesson is not "don't disrupt healthcare." The lesson is that disrupting healthcare requires building the clinical institution first and the consumer brand second — a sequence that no venture-backed DTC company of the 2010s had the patience or the capital structure to follow.
The building in Antioch stands empty. The sign is down. The printers are scattered across a dozen secondhand equipment dealers. But the questions SmileDirectClub raised — about who gets to straighten teeth, and how, and at what price, and under whose supervision — remain unanswered, waiting for a company with the operational depth and institutional patience to answer them properly.
